Kevin McLaughlin, MD
Otolaryngology · Covington, LANPI 1548269772
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $147,260 of the $185,818 with a category attached, or 79.2%. Optinose US, Inc. accounts for 95.2% of it on its own, with 21 other manufacturers making up the rest. Among otolaryngology clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 352 payments — averaging $527.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Optinose US, Inc.$177K
- Inspire Medical Systems, Inc.$7K
- Sanofi$547
- Acclarent, Inc$463
- Regeneron Healthcare Solutions, Inc.$186
- Arrinex, Inc.$160
- plus $908 from 16 others
Across 2 payments — averaging $875.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Intersect ENT, Inc.$2K
What the payments were for
- Consulting fees$2,5001%
- Speaking & faculty fees$147,26079%
- Travel & lodging$24,56513%
- Food & beverage$11,4586%
- Education$340%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Optinose US, Inc. | 197 | $176,849 |
| Inspire Medical Systems, Inc. | 91 | $6,705 |
| Sanofi | 17 | $547 |
| Acclarent, Inc | 10 | $463 |
| Regeneron Healthcare Solutions, Inc. | 3 | $186 |
| Arrinex, Inc. | 1 | $160 |
| Medtronic | 5 | $119 |
| Alk-abello, Inc | 3 | $113 |
| Tactile Systems Technology Inc | 1 | $101 |
| GSK | 5 | $100 |
| KARL Storz Endoscopy-america | 3 | $89 |
| Smith+Nephew | 2 | $80 |
| Integra Lifesciences Corporation | 4 | $71 |
| Stryker | 2 | $55 |
| Acera Surgical, Inc. | 1 | $43 |
| Amgen | 1 | $34 |
| Hikma Pharmaceuticals USA | 1 | $22 |
| Jazz Pharmaceuticals Inc. | 1 | $22 |
| AstraZeneca | 1 | $17 |
| Paratek Pharmaceuticals, Inc. | 1 | $15 |
| Itamar Medical Inc | 1 | $15 |
| Novartis | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Xhance$175,025
- Inspire$3,475
- Inspire Upper Airway Stimulation System$1,997
- DUPIXENT$177
- CLARIFIX$160
- Acclarent Aera$123
- FLEXITOUCH$101
- ACTITOUCH$101
- ENTRE$101
How this compares
$185,818 in reported general payments places this provider in the 95th percentile of 218 otolaryngology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XhanceFluticasone Propionate | 20 | $12,738 |
| Azelastine Hcl | 193 | $4,466 |
| Ipratropium Bromide | 129 | $3,875 |
| Mupirocin | 71 | $3,550 |
| Cevimeline Hcl | 28 | $3,330 |
| Pantoprazole Sodium | 216 | $2,377 |
| Fluticasone Propionate | 193 | $2,162 |
| Gabapentin | 116 | $1,634 |
| Armodafinil | 17 | $1,186 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 45 | $1,095 |
| Eszopiclone | 68 | $1,018 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 100 | $992 |
| Pramipexole DihydrochloridePramipexole Di-Hcl | 14 | $772 |
| Ropinirole Hcl | 39 | $598 |
| Levothyroxine Sodium | 28 | $548 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Optinose US, Inc.Xhance | $176,849 | $12,73820 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 218 otolaryngology providers in Louisiana.
Other otolaryngology in Covington
- Brad LebertCovington$7K
- Emily KamenCovington$4K
- Donald GonzalesNew Orleans$351K
- Adil FatakiaMarrero$148K
- Edward McCoulNew Orleans$92K
- Michael YimShreveport$77K
- Maura CosettiShreveport$64K
- Lizabeth ClarkeNew Iberia$40K
- Henry BarhamBaton Rouge$32K
- Cherie-Ann NathanShreveport$32K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.